Question - Immune checkpoint inhibitor Pembrolizumab
A patient is newly prescribed with pembrolizumab 200 mg IV every three weeks, an immunotherapeutic agent for the treatment of metastatic lung carcinoma.
a) What information would you obtain prior to dispensing/preparing this medication? (6 marks)
b) Please describe three possible immune-mediated reactions associated with this medication (6 marks)
c) After the second dose of pembrolizumab, the patient reports of having 4-6 stools per day, occasionally with blood. Please state how the situation should be managed. (3 marks)